GlassScriptPhysician profile
Muhammad A Shafqet
NPI 1801226873
$8,352.06
in general payments reported to CMS, 2019-2025
11 companies · $2,563 in 2025
The $2,563 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,163 · 2020: $298 · 2021: $274 · 2022: $3,422 · 2023: $395 · 2024: $237 · 2025: $2,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,017 · Food and Beverage: $1,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,017.17 |
| Food and Beverage | $1,177.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $4,191.36 | 2022-2025 | Disposable Distal Attachment, Single Use Electrosurgical Knife Kd-655 |
| Boston Scientific Corporation | $1,647.50 | 2019-2025 | Overstitch Endoscopic Suturing System, Exalt Model D, Orise |
| Abbvie INC. | $1,240.03 | 2019-2024 | Linzess, Viberzi, Skyrizi |
| Apollo Endosurgery US INC | $958.20 | 2019-2020 | |
| Cook Medical LLC | $136.99 | 2019 | |
| Covidien LP | $49.63 | 2020 | |
| Janssen Biotech, INC. | $44.11 | 2021-2022 | |
| Olympus America INC. | $35.50 | 2019 | |
| Ardelyx, INC. | $19.69 | 2024 | Ibsrela |
| Conmed Corporation | $15.26 | 2025 | Conmed Hemostasis |
| Merck Sharp & Dohme LLC | $13.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Shafqet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.